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Introduction
　Liver cancer causes 115,300 cancer deaths annually in 
developed countries[1], and ranks as the 5th leading cause of 
cancer death in Japan. In 2016, 42,800 new cases of liver 
cancer were diagnosed, and 26,000 patients died from this 
disease in 2018 in Japan[2]. 
　There are three main types of liver cancer: hepatocellular 
carcinoma (HCC), bile duct carcinoma, and mixed-type 
HCC. HCC accounts for the majority of primary liver cancer 
cases (70-90%). 
　The prognosis of HCC remains poor, with 5-year survival 
rates ranging between 12 and 23%[3], and life expectancy is 
difficult to predict because of various factors, such as alpha-
fetoprotein (AFP) levels, prothrombin induced by vitamin K 
absence-II (PIVKA-II) levels, portal vein thrombosis, the 
tumor stage, and the high recurrence of tumors. Approximately 
75% of patients with HCC have AFP levels higher than 10 
µg/L[4]. Previous studies identified serum AFP as an important 
indicator of postoperative HCC recurrence and metastasis[5], 
and high serum AFP levels have been associated with larger 
tumors, bilobar involvement, massive or diffuse-type tumors, 
and portal vein thrombus[6]. PIVKA-II is another serum 
marker used in the surveillance of at-risk patients and the 
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diagnosis of HCC, including the early stages[7–9]. According 
to the recommendations of the Clinical Practice Guidelines, 
the combination of AFP and PIVKA-II is currently used in 
Japan to diagnose HCC. 
　The prognosis of patients with HCC is generally poor and 
life expectancy is difficult to predict. Therefore, the accurate 
imaging of HCC is important. Only patients with small tumors 
and no extrahepatic metastases are potentially curable. 
Widely accepted imaging modalities to stage HCC are 
computed tomography (CT) and contrast-enhanced magnetic 
resonance imaging (MRI). However, CT and MRI have 
limited abilities to detect distant metastasis. Previous studies 
reported the role of 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography (18F-FDG-PET/CT) in 
the detection of gastrointestinal malignancies, such as gastric 
cancer, pancreatic cancer, and liver cancer[10–12]. Further-
more, 18F-FDG-PET/CT is a useful diagnostic tool for evalu-
ating extrahepatic metastasis[13]. However, the sensitivity of 
18F-FDG PET for detecting intrahepatic HCC is low[14,15].
　The usefulness of dual-time-point 18F-FDG PET/CT for 
differentiating between benign and malignant lesions has been 
demonstrated[16–19], and dual-time PET/CT was recently 
shown to be advantageous for the diagnosis of HCC[20]. 
　FDG PET/CT-derived parameters, such as standardized 
uptake values (SUV), metabolic tumor volume (MTV), and 
total lesion glycolysis (TLG), were recently proposed as 
prognostic factors for various tumors[21–23]. 
　The purpose of the present study was to investigate rela-
tionships between FDG PET parameters and other parameters 
that may influence the prognosis of patients with HCC.
Materials and methods
Patients
　We conducted a retrospective study on 26 patients with 
HCC who underwent dual-time-point FDG PET imaging 
before treatment between June 2010 and April 2016 at Naga-
saki University Hospital. There were 26 patients (20 males 
and 6 females) with a mean age of 71.5 years. Twelve 
(46.2%) patients had HCV infection, 7 (26.9%) HBV infection, 
and 7 (26.9%) alcoholic liver disease. 
　Prior to FDG PET, nine patients had history of surgical 
resection (34.6%), 5 (19.2%) transarterial embolization (TAE), 
5 (19.2%) transarterial chemoembolization (TACE), 4 (15.3%) 
radiofrequency ablation (RFA), 1 (3.8%) transcatheter arterial 
infusion (TAI), and 1 (3.8%) percutaneous ethanol injection 
(PEI). Eight patients did not receive any treatment before 
FDG PET/CT imaging, while some patients received several 
different types of therapy, such as RFA twice and TACE 
once. 
　All patients who had biopsy-proven HCC and underwent 
dual-time-point FDG PET examinations 1 hour (early) and 2 
hours (delayed) after the injection at our hospital were 
included in the present study. This study was approved by 
the Ethics committee of Nagasaki University Hospital 
(approved number: 17012308).
PET/CT protocol
　18F-FDG PET was performed using a PET scanner (Siemens 
mCT, Germany). All patients were instructed to refrain from 
consuming food and sweet drinks at least 5 hours before the 
scan. Early PET/CT imaging was performed 1 hour after the 
intravenous injection of approximately 200~300 MBq of 
FDG. Patients were scanned from the middle of the thigh to 
the top of the skull. Delayed scanning was conducted 
approximately 2 hours after the 18F-FDG injection and images 
were acquired from the upper abdominal cavity only.
　Images were reconstructed using the ordered subset 
expectation maximization algorithm and the following 
parameters: 200×200 matrix, field of view: 815 mm, two 
iterations, 24 subsets, and a 6-mm Gaussian filter. 
FDG-PET parameters 
　Some PET-related parameters are indicative of tumor 
activity. PET images are generally converted to standardized 
uptake values (SUV). SUV are calculated as the tissue activity 
concentration (Bq/ml) multiplied by body weight (g) divided 
by the injected dose (Bq); therefore, they account for inter-
individual differences in body mass and the injected tracer 
dose. Numerous parameters may be calculated based on 
SUV. The SUVmax of a tumor is defined as the maximum 
uptake value among all voxels. The SUVpeak of a tumor is 
defined as the average SUV for a 1-cm3 spherical volume 
around the SUVmax and aims to minimize fluctuations in 
measured activity caused by poor signal/noise ratios, which 
may affect SUVmax. The mean SUV (SUVmean) of the liver 
(as a normal organ) is used to calculate the tumor background 
ratio (TBR), which is defined as the ratio of the SUVmax of 
a lesion to the SUVmean of the liver (background). Further-
more, a number of volumetric parameters may be obtained 
from FDG PET images. For example, the metabolic tumor 
volume (MTV; cm3) is defined as the volume of a tumor that 
exhibits FDG uptake. In contrast to SUVmax, which represents 
the maximum single-voxel FDG uptake value of a tumor, 
MTV quantifies the overall tumor burden. In addition, total 
lesion glycolysis (TLG; g) may be calculated using the 
following formula: the SUVmean of a tumor × MTV.
83Altay Myssayev et al.: FDG PET, tumor marker and survival of HCC
HCC parameters
　HCC parameters were extracted from the disease history 
of each patient. AFP and PIVKA-II levels were measured 1 
month before imaging, the duration of the follow-up, the 
type of therapy (such as transarterial embolization (TAE), 
transarterial chemoembolization (TACE), radiofrequency 
ablation (RFA), and surgery), and the number of therapies 
received before FDG PET/CT imaging were recorded. 
Image analysis
　All FDG PET images were extracted from the electronic 
archival system at Nagasaki University Hospital and were 
visually inspected. In each case, a semi-quantitative evaluation 
was performed after the visual qualitative identification of 
the primary lesion. The SUVmax, SUVpeak, TLG, and MTV 
of the tumor and the SUVmean of the liver were evaluated 
on PET images using Metavol software[24]. 
　To assess SUVmax, the spherical volume of interest 
(VOI), which included the entire lesion in the axial, sagittal, 
and coronal planes, was examined. CT images were used to 
ensure that the 18F-FDG uptake of normal organs, such as the 
bowel and stomach, was not included in VOI. The following 
PET-related parameters were measured: the SUVmax of the 
tumor, which was defined as SUV for the point that exhibited 
the greatest tracer uptake (the hottest voxel); the SUVpeak 
of the tumor, defined as the average SUV within a 1-cm3 
spherical volume around SUVmax; the SUVmean of the 
liver (as a normal organ); MTV, defined as the volume of the 
tumor that exhibited FDG uptake; and TBR, defined as the 
ratio of the SUVmax of the tumor to the SUVmean of the 
liver (background). Tumors were delineated to assess tumor 
volumes. To achieve this, tumor images were segmented using 
the fixed-threshold method, and an SUVmax threshold value 
of ≥2.5, as recommended in many previous studies due to its 
simplicity and objectivity, was used to identify tumors[25–28]. 
TLG was calculated as follows: the SUVmean of a tumor × 
MTV. 
　We also determined visibility of tumor on FDG PET and 
measured its size. Visibility of FDG PET was reviewed by 
two observers (MY and TK) separately and determined as 
"with uptake" when FDG uptake was visible on PET only 
display of FDG PET/CT images. Tumor size on PET image 
and on CT image was measured on PET only display and CT 
only display of FDG PET/CT data, and longest axis length 
was determined as tumor size. When contrast-enhanced CT 
within one month was available, that image was also used as 
a reference for the CT size measurement. In case of discrepancy, 
the reviewers reached a consensus with discussion.
Statistical analysis
　All statistical analyses were performed using JMP Pro11 
software. All quantitative data are presented as median values 
with ranges, unless otherwise noted. Log transformation was 
used on AFP and PIVKA-II levels to account for the large 
range of values among the groups for both markers. Wilcoxon 
test was employed to compare continuous variables, and 
ANOVA test was performed to compare categorical variables. 
A Kaplan-Meier survival analysis was performed to calculate 
the Event-free survival (EFS). P-values of <0.05 were 
considered to be significant.
　Outcome definitions. Event-free survival was defined as 
the period from the date of the initiation of chemotherapy 
until evidence of an EFS event (progressive disease, death, 




　The subjectsʼ characteristics are listed in Table 1.
　The measured MTV was 0.0 cm3 in 16 patients because 
the tumor SUV max was less than the threshold value of 
≥2.5.  
　The distribution of TNM staging is presented in Table 2.
　The results of statistical analyses of the relationships between 
FDG PET/CT parameters and HCC parameters are listed in 
Tables 3-6.
　Relationship between SUV max-early and log AFP and 
log PIVKA-II presented on Figure 1.
　Table 3 summarizes relationship between FDG PET/CT 
parameters and AFP, PIVKA II.  Log AFP and log PIVKA II 
showed strong relationships between most of FDG parameters: 
SUV max (P=0.0004 and P=0.0001, respectively), SUV 
peak (P=0.0189 and P=0.0179, respectively) and TBR 
(P=0.0002 and P=0.0002, respectively).  
　Table 4 and 5 summarizes relationship between number of 
the several types of therapies performed prior to FDG PET 
and FDG PET/CT parameters, AFP, PIVKA II. Numbers of 
several types of therapy performed before the introduction 
of FDG PET showed some relationships but few of FDG 
parameters: TBR e and TACE (P=0.031), RFA (P=0.031), 
ΔTBR and surgery (P=0.078). Relationships between AFP, 
PIVKA II, and number of therapies were only found between 
log AFP and the number of TACE (P=0.0125).
　Table 6 summarizes relationship between total number of 
therapies and parameters of FDG PET/CT, AFP, PIVKA II. 
Significant correlation was only found betweenΔTLG and 
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number of therapies (P=0.0207).
　In the event-free survival analysis, patients were separated 
into those with and without PET uptake based on a visual 
inspection. Patients were also divided (into two even num-
ber groups) according to tumor sizes on PET images (small 
tumor size; large tumor size) and CT images (small tumor 
size; large tumor size). 
　The results of the event-free survival analysis revealed 
that patients with larger tumors on PET images had a poorer 
prognosis (Figure 2).






SUVmax-early (median, range) 5.27 (2.58-25.65)
SUVmax-delay (median, range) 5.21 (2.41-33.22)
SUVpeak-early (median, range) 6.63 (2.7-23.3)
SUVpeak-delay (median, range) 6.48 (2.35-29.58)
TBR-early (median, range) 2.02 (1.04-8.53)
TBR-delay (median, range) 2.22 (1.15-12.76)
MTV-early (cm3) (median, range) 103.44 (1.84-750.78)
MTV-delay (cm3) (median, range) 25.42 (0.19-115.85)
TLG-early (g) (median, range) 448.69 (4.93-2927.31)
TLG-delay (g) (median, range) 163.1 (0.53-1086.78)
Follow-up (months) (mean, range) 33.3 (1-144)
Alpha-fetoprotein (ug/L) (median, range) 17509.59 (2-346217)
PIVKA-II (ug/L) (median, range) 6884.05 (3.4-122044)
*SUV, standardized uptake value; SUVmax, maximum uptake value among all voxels; SUVpeak, average SUV for 
a 1-cm3 spherical volume around the SUVmax; TBR, tumor background ratio; MTV, metabolic tumor volume; TLG, 
total lesion glycolysis.
Table 2. Distribution of TNM and clinical staging. 
TNM stage Number of patients Clinical staging Number of patients
T1 10 I 9
T2 11 II 8
T3 5 III a 2
N0 25 III b 1
N1 1 IV a 1
M0 21 IV b 5
M1 5
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Table 3. Relationships between FDG PET parameters and HCC parameters (p-value).
FDG PET parameters Hepatocellular carcinoma parameters
Log AFP Log PIVKA-II
R2 P value R2 P value
SUV max e 0.4323 0.0004 0.5082 0.0001
SUV max d 0.3880 0.0033 0.4346 0.0016
Δ SUV max 0.3682 0.0046 0.0490 0.3482
SUV peak e 0.5684 0.0189 0.5749 0.0179
SUV peak d 0.5902 0.0156 0.8531 0.0004
Δ SUV peak 0.9478 0.0051 0.3724 0.2744
TBR e 0.4591 0.0002 0.4565 0.0002
TBR d 0.3395 0.0070 0.4258 0.0018
Δ TBR 0.3562 0.0055 0.1639 0.0766
*SUV, standardized uptake value; SUVmax, maximum uptake value among all voxels; SUVpeak, average SUV for a 1-cm3 spherical volume 
around the SUVmax; TBR, tumor background ratio.
Table 4. Relationships between FDG PET parameters and the number of several types of therapies performed prior to FDG PET (p-value). 




SUV max e SUV max d Δ SUV max SUV peak e TBR e TBR d Δ TBR
R2 P value R2 P value R2 P value R2 P value R2 P value R2 P value R2 P value
TAE
(n-19)
0.351 0.292 - - - - - - 0.231 0.412 - - - -
TACE
(n-13)
0.504 0.074 0.751 0.133 0.796 0.108 0.407 0.559 0.623 0.035 0.770 0.123 0.793 0.110
RFA
(n-6)
0.899 0.052 - - - - - - 0.940 0.031 - - - -
PEI
(n-1)
- - - - - - - - - - - - - -
TAI 
(n-1)
- - - - - - - - - - - - - -
Surgery
(n-7)
0.103 0.535 0.996 0.041 0.992 0.057 0.032 0.822 0.100 0.541 1.000 0.008 0.985 0.078
*SUV, standardized uptake value; SUVmax, maximum uptake value among all voxels; SUVpeak, average SUV for a 1-cm3 spherical volume around the 
SUVmax; TBR, tumor background ratio; TAE, transarterial embolization; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; PEI, 
percutaneous ethanol injection; TAI, transcatheter arterial infusion. 






Table 5. Relationships between hepatocellular carcinoma parameters and the number of several types of therapies 
performed prior to FDG PET (p-value).
Type of therapy Hepatocellular carcinoma parameters
Log AFP Log PIVKA II
R2 P  value R2 P  value
TAE (n-19) 0.0350 0.7632 0.0967 0.6104
TACE (n-13) 0.7435 0.0125 0.3776 0.1420
RFA (n-6) 0.3797 0.3838 0.7376 0.1411
PEI (n-1) - -
TAI (n-1) - -
Surgery (n-7) 0.2412 0.3225 0.4971 0.1176
*TAE, transarterial embolization; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; PEI, percutaneous 
ethanol injection; TAI, transcatheter arterial infusion.
Figure 1. Relationship between FDG uptake and AFP, PIVKA-II. 
*SUV, standardized uptake value; SUVmax early, maximum uptake value among all voxels in early image.
Figure 2. Outcomes of hepatocellular carcinoma cases: event-free survival and distribution by HCC parameters (a – grouped by 
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Table 6. Relationships between FDG PET parameters/hepatocellular carcinoma parameters 





R2 P  value
SUV max e 0.0322 0.4009
SUV max d 0.0473 0.3708
ΔSUV max 0.1137 0.1579
SUV peak e 0.0709 0.4884
SUV peak d 0.0135 0.7653
ΔSUV peak 0.6208 0.1134
TBR e 0.0424 0.3342
TBR d 0.0527 0.3441
ΔTBR 0.0938 0.2022
TLG e 0.1339 0.3327
TLG d 0.0292 0.6599
ΔTLG 0.8701 0.0207
MTV e 0.1281 0.3442
MTV d 0.0555 0.5415
Log AFP 0.1212 0.0954
Log PIVKA-II 0.0059 0.7202
*SUV, standardized uptake value; SUVmax, maximum uptake value among all voxels; SUVpeak, 
average SUV for a 1-cm3 spherical volume around the SUVmax; TBR, tumor background ratio; 
MTV, metabolic tumor volume; TLG, total lesion glycolysis. 
Discussion
　The present results showed that high FDG uptake correlated 
with the tumor burden, such as high AFP and PIVKA-II levels. 
Previous studies reported that high serum AFP and PIVKA-
II levels correlated with the poor prognosis (larger tumor 
size, more aggressive tumor characteristics, metastasis, and 
recurrence) of patients with HCC[5–7,29,30]. 
　AFP is a major plasma protein produced by the yolk 
sac and fetal liver during fetal development. It is regarded as 
a fetal analog of serum albumin. Serum AFP levels are very 
low in adults. AFP is currently used as a tumor marker for 
the diagnosis of HCC. However, it may be high in some non-
cancerous liver diseases and low in some patients with 
HCC[31,32]. Serum AFP levels are not only of diagnostic 
value, but also prognostic value in patients with HCC. 
　PIVKA-II is another serum marker that is used in the sur-
veillance of at-risk patients and the diagnosis of HCC, 
including the early stages[7–9]. PIVKA-II levels in the blood 
are elevated in patients with HCC. Previous studies demon-
strated that it is more sensitive than AFP for differentiating 
HCC at all stages from cirrhosis or chronic hepatitis[7,29,30]. 
In the present study, PIVKA-II levels were associated with 
tumor sizes on PET and CT images. Since the event-free 
survival analysis showed that patients with larger tumors on 
PET images had a poorer prognosis, the present results appear 
to support previous findings. The sensitivity of the combined 
measurement of PIVKA-II and AFP levels ranged between 
47.5 and 94%, with a specificity of between 53.3 and 98.5% 
in the early diagnosis of HCC, and these values were superior 
to those for either marker alone[33].
　FDG PET is a nuclear imaging technique that detects 
proliferating tumors based on their increased uptake and 
metabolism of glucose. Tumor cells generally exhibit strong 
glycolytic activity. Since 18F-FDG is a radiolabeled analog 
of glucose, 18F-FDG PET reveals tumors by highlighting 
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areas of elevated glycolytic activity in vivo, which allows 
for the 3D visualization of glucose metabolism. 18F-FDG 
PET has the advantage of providing scans of the whole body 
in one session, which allows for initial staging and reveals 
any distant metastasis or nodal involvement. Furthermore, 
18F-FDG PET detects tumors earlier than conventional imaging 
techniques and may be used to evaluate tumor aggressiveness 
and predict prognosis. The uptake of FDG has been shown 
to correlate with tumor activity and growth. Therefore, high 
FDG uptake correlates with a poor prognosis. The present 
results are consistent with these findings. 
　Since there are many FDG/PET CT-derived parameters, 
there may be confusion among clinicians regarded the most 
appropriate parameters to use. Metabolic FDG PET/CT-
derived parameters, such as SUV-based parameters and vol-
umetric parameters, including MTV and TLG, have been 
proposed as prognostic factors for various tumors[12,21–23]. 
However, the use of volumetric parameters in the present 
study was limited because of the difficulties associated with 
defining the tumor margin in some HCC due to the low uptake 
of FDG. 
　Cho et al.[34] reported a strong correlation between the 
tumor and background ratio and factors associated with the 
biological behavior of HCC, which may be used as a predictive 
factor for overall survival. However, all patients in the present 
study had chronic hepatitis or alcoholic liver cirrhosis, both 
of which alter 18F-FDG uptake. Therefore, background liver 
uptake may also be affected, and increased uptake by liver 
tumors may be masked by background liver hepatitis or liver 
cirrhosis. In the present study, increased TBR correlated 
with a more aggressive tumor burden characterized by higher 
AFP and PIVKA-II levels. 
　Therapeutic interventions may also influence FDG PET 
parameters; however, only an equivocal relationship was 
noted in the present study. 
　Increased FDG uptake in HCC patients reflects the ag-
gressive biological activity of tumors and is associated with 
poor survival. Therefore, patients with high FDG uptake 
may respond poorly to treatment[35,36]. In a previous study 
by Kim et al.[37], a patient group with high SUV showed a 
significantly stronger objective tumor response than a patient 
group with low SUV. Despite the strong tumor response, 
patients with high SUV had worse overall survival due to the 
occurrence of distant metastasis. Strongly proliferating tumors 
are radiosensitive, and HCC with high FDG uptake are 
considered to respond better to radiotherapy than those with 
low uptake[37]. However, HCC with high FDG uptake also 
have a high risk of early recurrence and distant metastasis
[38,39]. Therefore, viable tumor cells in residual lesions 
after radiotherapy may spread more rapidly and frequently 
to extrahepatic organs, resulting in worse overall survival[40]. 
Collectively, these findings indicate that HCC have different 
responses to treatment based on the degree of FDG uptake. 
Multiple treatments, including radiotherapy, may be more 
effective for tumor control in patients with high FDG uptake, 
while HCC with low FDG uptake were affected less by the 
treatment modality. HCC with low and high FDG uptakes 
have different tumor characteristics, genetic dispositions, 
and recurrence rates; therefore, different treatment strategies 
may need to be employed based on the findings of FDG 
uptake in these patients. 
　The present study has several limitations. FDG PET/CT 
images and patient follow-up data were retrospectively ana-
lyzed. Furthermore, the number of patients with HCC was 
small, which may have limited our conclusions. In addition, 
the number of HCC cases for each type of treatment modality 
was small, except for surgery, which showed a correlation. 
Another limitation is that VOI were drawn and analyzed by 
two radiologists based on a consensus approach. We did not 
assess inter- or intraobserver variabilities in the placement of 
VOI or its effects on the results obtained. Moreover, MTV 
and TLG were calculated as the 2.5 SUVmax threshold value, 
which may potentially underestimate these parameters in 
some HCC patients. PET imaging with alternative radiotracers 
may be useful for HCC with low FDG uptake.
Conclusion
　In the present study, relationships were observed between 
FDG PET parameters and AFP and PIVKA II levels, which 
affect the prognosis of patients with HCC. Based on the 
present results and previous findings, FDG parameters in 
combination with serum AFP and PIVKA II levels may be 
useful for predicting the outcomes of patients with HCC.
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